Skip to main content

Table 2 Subject information and clinical evaluations

From: Novel transcriptional profile in wrist muscles from cerebral palsy patients

Sub Sex Age Muscle SL (μm) House Sev Ash Zan PEFF (°) PESF (°) AEFF (°) MyHC gel
AI M 13 FCU 6.36 1 SS 4 3 -5 -90 -70 x
    ECRB          x
AN F 12 FCU 4.56 3 SS 3 2B 50 45 -90  
    ECRB          
AO F 11 FCU 4.01 5 SM 2 2B 65 60 -50 x
    ECRB          x
AQ M 15 FCU 4.01 7 M 2 2B 80 80 -50  
    ECRB          
AT M 14 FCU 3.57 0 SS 3 3 45 40   
    ECRB          
BF F 12 FCU 5.31 6 SM 3 2A 85 85 55 x
    ECRB          x
BP M 10 FCU - - C 1 0 90 90 90 x
    ECRB          
AZ M 7 FCU - - C 1 0 90 90 90 x
    ECRB          x
  1. Table of the eight subjects used in this study with 2 muscles (FCU and ECRB) per patient with sex and age recorded. Measures of severity were taken to include: intraoperative measurement of sarcomere length (SL) on the FCU, House clinical assessment of activity, Severity (Sev) grouped by House (Severe Severe (SS), Severe Moderate (SM), Mild (M), and Control (C)), Ashworth (Ash) clinical assessment, Zancolli (Zan) classification based on finger extension, passive extension with flexed fingers (PEFF) passive extension with straight fingers (PESF) and active extension with flexed fingers (AEFF). Samples that were available for MyHC SDS-PAGE gels are noted in the final column